Shares of Editas Medicine (NASDAQ: EDIT) were soaring 15.4% higher as of 11:05 a.m. EST on Monday. The big gain came after Editas presented new data for its gene-editing candidate EDIT-301 at the American Society of Hematology (ASH) annual meeting held virtually on Saturday.
The presentations at the annual ASH meeting often provide catalysts for quite a few biotech stocks. The good news for EDIT-301 certainly warranted a nice bump for Editas' shares.
Image source: Getty Images.
One of the challenges of gene editing is editing enough cells to make a difference in treating a disease. Editas announced that high levels of editing in red blood cells obtained from patients with and without sickle cell disease were achieved in preclinical testing. Most importantly, this led to robust induction of fetal hemoglobin and resulted in what the biotech said was "remarkable correction" of sickle cell disease in cells.
Another challenge for gene-editing therapies is making them in large quantities. Editas stated that its "large-scale manufacturing process was shown to be consistent and robust."
Editas is well behind CRISPR Therapeutics and its big partner Vertex Pharmaceuticals in the development of a gene-editing therapy for sickle cell disease and a related genetic blood disease beta-thalassemia. However, Editas thinks that EDIT-301 could be the best in its class, with a safer and more effective approach. The biotech expects to file for FDA approval by the end of this year to advance EDIT-301 into a phase 1 clinical study in treating sickle cell disease.
10 stocks we like better than Editas Medicine
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Editas Medicine wasn't one of them! That's right -- they think these 10 stocks are even better buys.
*Stock Advisor returns as of November 20, 2020
Keith Speights owns shares of Editas Medicine and Vertex Pharmaceuticals. The Motley Fool owns shares of and recommends CRISPR Therapeutics and Editas Medicine. The Motley Fool recommends Vertex Pharmaceuticals. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.